Half-Year 2022 Financial and Clinical Trials Update
Roche
Tecentriq
Anti-PD-L1 cancer immunotherapy - lung cancer
Indication
1L maintenance extensive-stage SCLC
2L NSCLC previously treated with an immune checkpoint inhibitor
Phase/study
# of patients
Design
Primary endpoint
☐
Phase III
IMforte1
N=450
ARM A: Platinum-etoposide + Tecentriq followed by maintenance
Tecentriq plus lurbinectedin
ARM B: Platinum-etoposide + Tecentriq followed by maintenance
Tecentriq
Progression-free survival and overall survival
Status
CT Identifier
☐
FPI Q4 2021
NCT05091567
1In collaboration with Jazz Pharma
NSCLC-non-small cell lung cancer; PD-L1=Programmed cell death-ligand 1; SCLC-small cell lung cancer;
Phase III
CONTACT-01
N=366
☐
ARM A: Tecentriq plus cabozantinib
ARM B: Docetaxel
Overall survival
FPI Q3 2020
Recruitment completed Q4 2021
NCT04471428
88
OncologyView entire presentation